The sulfonylurea controversy

More questions from the heart

Peter A. Brady, Andre Terzic

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Myocardial ischemia and infarction are associated with substantially increased morbidity and mortality among patients with diabetes mellitus. Although many factors contribute to the increased morbidity and mortality, in patients with non-insulin-dependent (type II) diabetes mellitus, one contributor may be the use of sulfonylurea drugs, the most widely used oral hypoglycemic agents. Such a possibility, which first arose over a 25 years ago when it was observed that patients taking sulfonylurea drugs had increased cardiovascular mortality, has recently resurfaced after the discovery that sulfonylureas act by inhibiting adenosine triphosphate (ATP)- sensitive potassium channels. In the pancreas, inhibition of ATP-sensitive potassium channels induces release of insulin; but in the heart, inhibition of these channels prevents ischemic preconditioning, an endogenous cardioprotective mechanism that protects the heart from lethal injury. This review outlines the current understanding of the molecular and cellular pharmacodynamics of sulfonylurea drugs and discusses the potential clinical consequences of inhibition of ATP- sensitive potassium channels in the heart of diabetic patients with cardiac disease in whom the use of sulfonylureas may be harmful.

Original languageEnglish (US)
Pages (from-to)950-956
Number of pages7
JournalJournal of the American College of Cardiology
Volume31
Issue number5
DOIs
StatePublished - Apr 1998

Fingerprint

Potassium Channels
Adenosine Triphosphate
Type 2 Diabetes Mellitus
Mortality
Pharmaceutical Preparations
Heart Injuries
Morbidity
Ischemic Preconditioning
Hypoglycemic Agents
Myocardial Ischemia
Pancreas
Heart Diseases
Diabetes Mellitus
Myocardial Infarction
Insulin

ASJC Scopus subject areas

  • Nursing(all)

Cite this

The sulfonylurea controversy : More questions from the heart. / Brady, Peter A.; Terzic, Andre.

In: Journal of the American College of Cardiology, Vol. 31, No. 5, 04.1998, p. 950-956.

Research output: Contribution to journalArticle

@article{be5da00025e842fc9092680da48a59d4,
title = "The sulfonylurea controversy: More questions from the heart",
abstract = "Myocardial ischemia and infarction are associated with substantially increased morbidity and mortality among patients with diabetes mellitus. Although many factors contribute to the increased morbidity and mortality, in patients with non-insulin-dependent (type II) diabetes mellitus, one contributor may be the use of sulfonylurea drugs, the most widely used oral hypoglycemic agents. Such a possibility, which first arose over a 25 years ago when it was observed that patients taking sulfonylurea drugs had increased cardiovascular mortality, has recently resurfaced after the discovery that sulfonylureas act by inhibiting adenosine triphosphate (ATP)- sensitive potassium channels. In the pancreas, inhibition of ATP-sensitive potassium channels induces release of insulin; but in the heart, inhibition of these channels prevents ischemic preconditioning, an endogenous cardioprotective mechanism that protects the heart from lethal injury. This review outlines the current understanding of the molecular and cellular pharmacodynamics of sulfonylurea drugs and discusses the potential clinical consequences of inhibition of ATP- sensitive potassium channels in the heart of diabetic patients with cardiac disease in whom the use of sulfonylureas may be harmful.",
author = "Brady, {Peter A.} and Andre Terzic",
year = "1998",
month = "4",
doi = "10.1016/S0735-1097(98)00038-2",
language = "English (US)",
volume = "31",
pages = "950--956",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - The sulfonylurea controversy

T2 - More questions from the heart

AU - Brady, Peter A.

AU - Terzic, Andre

PY - 1998/4

Y1 - 1998/4

N2 - Myocardial ischemia and infarction are associated with substantially increased morbidity and mortality among patients with diabetes mellitus. Although many factors contribute to the increased morbidity and mortality, in patients with non-insulin-dependent (type II) diabetes mellitus, one contributor may be the use of sulfonylurea drugs, the most widely used oral hypoglycemic agents. Such a possibility, which first arose over a 25 years ago when it was observed that patients taking sulfonylurea drugs had increased cardiovascular mortality, has recently resurfaced after the discovery that sulfonylureas act by inhibiting adenosine triphosphate (ATP)- sensitive potassium channels. In the pancreas, inhibition of ATP-sensitive potassium channels induces release of insulin; but in the heart, inhibition of these channels prevents ischemic preconditioning, an endogenous cardioprotective mechanism that protects the heart from lethal injury. This review outlines the current understanding of the molecular and cellular pharmacodynamics of sulfonylurea drugs and discusses the potential clinical consequences of inhibition of ATP- sensitive potassium channels in the heart of diabetic patients with cardiac disease in whom the use of sulfonylureas may be harmful.

AB - Myocardial ischemia and infarction are associated with substantially increased morbidity and mortality among patients with diabetes mellitus. Although many factors contribute to the increased morbidity and mortality, in patients with non-insulin-dependent (type II) diabetes mellitus, one contributor may be the use of sulfonylurea drugs, the most widely used oral hypoglycemic agents. Such a possibility, which first arose over a 25 years ago when it was observed that patients taking sulfonylurea drugs had increased cardiovascular mortality, has recently resurfaced after the discovery that sulfonylureas act by inhibiting adenosine triphosphate (ATP)- sensitive potassium channels. In the pancreas, inhibition of ATP-sensitive potassium channels induces release of insulin; but in the heart, inhibition of these channels prevents ischemic preconditioning, an endogenous cardioprotective mechanism that protects the heart from lethal injury. This review outlines the current understanding of the molecular and cellular pharmacodynamics of sulfonylurea drugs and discusses the potential clinical consequences of inhibition of ATP- sensitive potassium channels in the heart of diabetic patients with cardiac disease in whom the use of sulfonylureas may be harmful.

UR - http://www.scopus.com/inward/record.url?scp=0032053572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032053572&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(98)00038-2

DO - 10.1016/S0735-1097(98)00038-2

M3 - Article

VL - 31

SP - 950

EP - 956

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -